Ocugen Inc. is dedicated to developing therapies for serious eye conditions, leveraging its expertise in gene therapy.

In addition to its current trials, Ocugen plans to expand its pipeline with additional gene therapy candidates that target other ocular diseases.

Ocugen has reported advancements in its gene therapy trials, further solidifying its commitment to addressing ocular diseases.

The company's lead candidate, OCU400, is currently undergoing clinical trials aimed at treating retinitis pigmentosa, a genetic eye disorder that can lead to blindness.

Early results from these trials have been promising, suggesting the potential effectiveness of OCU400 in improving vision for affected patients.

The company remains optimistic about the regulatory pathways for its gene therapies and is preparing for potential future commercialization.